Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

Recruiting now · Phase 4

Conditions studied: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis

In brief

The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.

Key facts

Study ID

NCT07695701

Run by

Eidos Therapeutics, a BridgeBio company

People needed

150

Starts

2026-07-01

Expected to finish

2030-11-01

Last updated by the study team

2026-07-29

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Washington University in St. Louis — St Louis, Missouri, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.